Therapy-related leukemia: is the risk life-long and can we identify patients at greatest risk

American Journal of Pediatric Hematology/Oncology

Volumn 22, Issue 4, 2000, Pages 302-305

  Davies, Stella M ^a  

^a UNIV OF MINNESOTA HOSP AND CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; GLYCOPHORIN A; HEMOPOIETIC GROWTH FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RISK; EWING SARCOMA; GENETIC SUSCEPTIBILITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; LEUKEMIA; MYELODYSPLASIA; NONHODGKIN LYMPHOMA; NOTE; PATIENT SELECTION; PRIORITY JOURNAL; SECOND CANCER;

ACUTE DISEASE; CHILD; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LEUKEMIA, MYELOID; NEOPLASMS, SECOND PRIMARY; RISK FACTORS; TIME FACTORS;

EID: 0034456471     PISSN: 01928562     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200007000-00005     Document Type: Editorial

References (27)

1. Frei E, Teicher BA, Holden SA, et al. Preclinical studies and clinical correlation of the effect of alkylating agent dose. Cancer Res 1989;48:6417-23.
2. Gulati SC, Kwon JH, Atzpodien J, et al. in vitro chemosensitivity of two Ewing's sarcoma cell lines: implications for autologous bone marrow transplantation. Cancer Invest 1989;7:411-16.
3. Brock N. Oxazophosphorine cytostatics: past-present-future. Cancer Res 1989;49:1-7.
4. Hawkins MM, Risks of myeloid leukemia in children treated for solid tumors. Lancet 1990;336:887.
5. Miller JS, Arthur DC, Litz CE, Neglia JP, Miller WJ, Weisdorf DJ. Myelodysplastic syndrome after autologous bone marrow transplantation: An additional late complication of curative cancer therapy. Blood 1994;83:3780-6.
6. Stone RM, Neuberg D, Soiffer R, et al. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for Non-Hodgkin's lymphoma. J Clin Oncol 1994;12:2535-42.
7. Darrington DL, Vose JM, Anderson JR, et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem cell transplantation for lymphoid malignancies. J Clin Oncol 1994;12:2527-34.
8. Bhatia S, Robison LL, Oberlin O, et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 1996;334:745-51.
9. Blayney DW, Longo DL, Young RC, et al. Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherapy for Hodgkin's disease. N Engl J Med 1987;316:710-4.
10. Jenkin D, Greenberg M, Fitzgerald A. Second malignant tumors in childhood Hodgkin's disease. Med Pediatr Oncol 1996;26:373-9.
11. Sankila R, Garwicz S, Olsen JH, et al. For the Association of the Nordic Cancer Registries and the Nordic Society of Pediatr Hematol Oncol: Risk of subsequent malignant neoplasms among 1,641 Hodgkin's disease patients diagnosed in childhood and adolescence: A population-based cohort study in the five Nordic countries. J Clin Oncol 1996;14: 1442-6.
12. Beaty O, Hudson MM, Greenwald C, et al. Subsequent malignancies in children and adolescents after treatment of Hodgkin's disease. J Clin Oncol 1995;13:603-09.
13. Dietrich PY, Henry-Amar M, Cosset JM, Bodis S, Bosq J, Hayat M. Second primary cancers in patients continuously disease-free from Hodgkin's disease: A protective role for the spleen? Blood 1994;84:1209-15.
14. Abrahamsen JF, Andersen A, Hannisdal E, Nome O, Foss Abrahamsen A, Kvaloy S, Host H. Second malignancies after treatment of Hodgkin's disease: The influence of treatment, follow-up time, and age. J Clin Oncol 1993;11:255-61.
15. Salvagno L, Simonato L, Soraru M, et al. Secondary leukemia following treatment of Hodgkin's disease. Tumori 1993;79:103-7.
16. Tura S, Fiacchini M, Zinzani PL, Brusamolino E, Gobbi PG. Splenectomy and the increasing risk of secondary acute leukemia in Hodgkin's disease. J Clin Oncol 1993;11:925-30.
17. Cimino G, Papa G, Tura S, et al. Second primary cancer following Hodgkin's disease: Updated results of an Italian multicentric study. J Clin Oncol 1991;9:432-7.
18. Andrieu J-M, Ifrah N, Payen C, Fermanian J, Coscas Y, Flandrin G. Increased risk of secondary acute nonlymphocytic leukemia after extended-field radiation therapy combined with MOPP chemotherapy for Hodgkin's disease. J Clin Oncol 1990;8:1148-54.
19. Devereux S, Selassie TG, Vaughan Hudson G, Vaughan Hudson B, Linch DC. Leukaemia complicating treatment of Hodgkin's disease: The experience of the British National Lymphoma Investigation. BMJ 1990;301:1077-80.
20. Koletsky AJ, Bertino JR, Farber LR, et al. Second neoplasms in patients with Hodgkin's disease following combined modality therapy-the Yale experience. J Clin Oncol 1986;4:311-7.
21. Felix CA, Walker AH, Lange BJ, et al. Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci USA 1998;95:13176-81.
22. Davies SM, Robison LL, Buckley J, et al. GST polymorphisms in 1017 children with acute leukemia: a Children's Cancer Group (CCG) study. Med Pediatr Oncol 1999;33:174(abstract).
23. Mott MG, Boyse J, Hewitt M, Radford M. Do mutations at the glycophorin A locus in patients treated for childhood Hodgkin's disease predict secondary leukaemia? Lancet 1994;343:828-9.
24. Boyse J, Hewitt M, Mott MG. Glycophorin A mutations and risk of secondary leukaemia in patients treated for childhood acute lymphoblastic leukaemia. Br J Haematol 1996;93:117-24.
25. Mach-Pascual S, Legare RD, Lu D, et al. Predictive value of clonality tests in patients with non-Hodgkin's lymphoma undergoing autologous stem cell transplant: a single institution study. Blood 1998;91:4496-503.
26. Taylor JA, Sandler DP, Bloomfield CD, et al. Ras oncogene activation and occupational exposures in acute myeloid leukemia. J Natl Cancer Inst 1992;84:1626-32.
27. Carter C, McGlynn H, Carter G, et al. RAS and FMS mutations following cytotoxic therapy for childhood acute lymphoblastic leukemia. Leukemia 1995;9:466-70.